Any ambitious biotech that wishes to go it alone on the market needs to get its key commercial team in place before planning late-stage studies, according to Tim Van Hauwermeiren, CEO of argenx N.V..
Van Hauwermeiren's views come with considerable weight given the stellar launch Argenx has enjoyed with Vyvgart (efgartigimod) which was approved...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?